This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

About Nembutal

When Emergency Control of SE Is Needed2 ... Consider Nembutal ®

About Nembutal 2017-05-03T06:26:10+00:00

nembutal-spread2

NEMBUTAL® Sodium Solution (pentobarbital sodium injection) is a sterile solution for intravenous or intramuscular injection. NEMBUTAL® Sodium is a short-acting barbiturate, chemically designated as sodium 5-ethyl-5-(1- methyl butyl) barbiturate. Each mL contains pentobarbital sodium 50 mg, in a vehicle of propylene glycol, 40%, alcohol, 10% and water for injection, to volume.  There are many good reasons to consider Nembutal when choosing an agent for sedation:

NembutalALL

Nembutal® is Fast and Potent for Sedation

  • Delivers rapid onset of action almost immediately1
  • Safe and effective, as a sedative, for patients undergoing CT or MRI procedures.5, 6

Nembutal® is Effective for Seizures

  • A recommended agent as cited in the 2012 “Guidelines for the Evaluation and Management of Status Epilepticus” from the Neurocritical Care Society4
  • Appropriate for seizure control in the pediatric, adult, and geriatric populations.1, 2, 3

Nembutal® is an Alternative When Other Sedatives are not Feasible

  • When oral sedation is not feasible1
  • Preservative free and can be used for patients with soy or egg allergies1
  • Does not present a risk of metabolic infusion syndrome1
  • Latex free vial stopper.

 

 

 

Nembutal-partial-Sell-sheet-table

See full prescribing information

Important Safety Information

CONTRAINDICATIONS
Barbiturates are contraindicated in patients with known barbiturate sensitivity. Barbiturates are also contraindicated in patients with a history of manifest or latent porphyria.

WARNINGS
1. Habit forming: Barbiturates may be habit forming. Tolerance, psychological and physical dependence may occur with continued use. Patients who have psychological dependence on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop a physical dependence on barbiturates.

To minimize the possibility of overdosage or the development of dependence, the prescribing and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions, and possibly death. Barbiturates should be withdrawn gradually from any patient known to be taking excessive dosage over long periods of time.

2. IV administration: Too rapid administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with fall in blood pressure.
3. Acute or chronic pain: Caution should be exercised when barbiturates are administered to patients with acute or chronic pain, because paradoxical excitement could be induced or important symptoms could be masked. However, the use of barbiturates as sedatives in the postoperative surgical period and as adjuncts to cancer chemotherapy is well established.

4. Use in pregnancy: Barbiturates can cause fetal damage when administered to a pregnant woman. Retrospective, case-controlled studies have suggested a connection between the maternal consumption of barbiturates and a higher than expected incidence of fetal abnormalities.

Withdrawal symptoms occur in infants born to mothers who receive barbiturates throughout the last trimester of pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

5. Synergistic effects: The concomitant use of alcohol or other CNS depressants may produce additive CNS depressant effects.

ADVERSE REACTIONS

The following adverse reactions and their incidence were compiled from surveillance of thousands of hospitalized patients. Because such patients may be less aware of certain of the milder adverse effects of barbiturates, the incidence of these reactions may be somewhat higher in fully ambulatory patients.

More than 1 in 100 patients. The most common adverse reaction estimated to occur at a rate of 1 to 3 patients per 100 is: Nervous System: Somnolence.

Less than 1 in 100 patients. Adverse reactions estimated to occur at a rate of less than 1 in 100 patients listed below, grouped by organ system, and by decreasing order of occurrence are:

Nervous system: Agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality.

Respiratory system: Hypoventilation, apnea.

Cardiovascular system: Bradycardia, hypotension, syncope.

Digestive system: Nausea, vomiting, constipation.

Other reported reactions: Headache, injection site reactions, hypersensitivity reactions (angioedema, skin rashes, exfoliative dermatitis), fever, liver damage, megaloblastic anemia following chronic phenobarbital use.

Please see Nembutal full prescribing information.